DAIDS Table for Grading the Severity of Adult and Pediatric Adverse ...

DIVISION OF AIDS TABLE FOR GRADING THE SEVERITY OF 

ADULT AND PEDIATRIC ADVERSE EVENTS 

VERSION 1.0, DECEMBER, 2004; CLARIFICATION AUGUST 2009 

The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (“DAIDS AE 

Grading Table”) is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A 

grading (severity) scale is provided for each AE term. 

This clarification of the DAIDS Table for Grading the Severity of Adult and Pediatric AE’s provides 

additional explanation of the DAIDS AE Grading Table and clarifies some of the parameters. 

I. Instructions and Clarifications 

Grading Adult and Pediatric AEs 

The DAIDS AE Grading Table includes parameters for grading both Adult and Pediatric AEs. When a 

single set of parameters is not appropriate for grading specific types of AEs for both Adult and Pediatric 

populations, separate sets of parameters for Adult and/or Pediatric populations (with specified respective 

age ranges) are given in the Table. If there is no distinction in the Table between Adult and Pediatric 

values for a type of AE, then the single set of parameters listed is to be used for grading the severity of 

both Adult and Pediatric events of that type. 

Note: In the classification of adverse events, the term “severe” is not the same as “serious.” 

Severity is an indication of the intensity of a specific event (as in mild, moderate, or severe chest 

pain). The term “serious” relates to a participant/event outcome or action criteria, usually 

associated with events that pose a threat to a participant’s life or functioning. 

Addenda 1-3 Grading Tables for Microbicide Studies 

For protocols involving topical application of products to the female genital tract, male genital area or 

rectum, strong consideration should be given to using Appendices I-III as the primary grading scales for 

these areas. The protocol would need to specifically state that one or more of the Appendices would be 

primary (and thus take precedence over the main Grading Table) for items that are listed in both the 

Appendix and the main Grading Table. 

• Addendum 1 - Female Genital Grading Table for Use in Microbicide Studies - PDF 

• Addendum 2 - Male Genital Grading Table for Use in Microbicide Studies - PDF 

• Addendum 3 - Rectal Grading Table for Use in Microbicide Studies - PDF 

Grade 5 

For any AE where the outcome is death, the severity of the AE is classified as Grade 5. 

Estimating Severity Grade for Parameters Not Identified in the Table 

In order to grade a clinical AE that is not identified in the DAIDS AE grading table, use the category 

“Estimating Severity Grade” located on Page 3. 

Determining Severity Grade for Parameters “Between Grades” 

If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could 

be either Grade 2 or Grade 3), select the higher of the two grades for the AE. If a laboratory value that is 

graded as a multiple of the ULN or LLN falls between two grades, select the higher of the two grades for 

the AE. For example, Grade 1 is 2.5 x ULN and Grade 2 is 2.6 x ULN for a parameter. If the lab value is 

2.53 x ULN (which is between the two grades), the severity of this AE would be Grade 2, the higher of the 

two grades. 

Values Below Grade 1 

Any laboratory value that is between either the LLN or ULN and Grade 1 should not be graded. 

28-Dec-04/Clarification Aug 09 Page 1 of 21 Version 1.0/Clarification 1




Determining Severity Grade when Local Laboratory Normal Values Overlap with Grade 1 Ranges 

In these situations, the severity grading is based on the ranges in the DAIDS AE Grading Table, even 

when there is a reference to the local lab LLN. 

For example: Phosphate, Serum, Low, Adult and Pediatric > 14 years (Page 20) Grade 1 range is 2.50 

mg/dL - < LLN. A particular laboratory’s normal range for Phosphate is 2.1 – 3.8 mg/dL. A participant’s 

actual lab value is 2.5. In this case, the value of 2.5 exceeds the LLN for the local lab, but will be graded 

as Grade 1 per DAIDS AE Grading Table. 

. 

II. Definitions of terms used in the Table: 

Basic Self-care Functions 

Adult 

Activities such as bathing, dressing, toileting, transfer/movement, 

continence, and feeding. 

Young Children 

Activities that are age and culturally appropriate (e.g., feeding self with 

culturally appropriate eating implement). 

LLN 

Medical Intervention 

NA 

Operative Intervention 

ULN 

Usual Social & Functional 

Activities 

Lower limit of normal 

Use of pharmacologic or biologic agent(s) for treatment of an AE. 

Not Applicable 

Surgical OR other invasive mechanical procedures. 

Upper limit of normal 

Adult 

Adaptive tasks and desirable activities, such as going to work, 

shopping, cooking, use of transportation, pursuing a hobby, etc. 

Young Children 

Activities that are age and culturally appropriate (e.g., social 

interactions, play activities, learning tasks, etc.). 

28-Dec-04/Clarification Aug 09 Page 2 of 21 Version 1.0/Clarification 1




PARAMETER GRADE 1 

MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 

LIFE-THREATENING 

ESTIMATING SEVERITY GRADE 

Clinical adverse event 

NOT identified 

elsewhere in this 

DAIDS AE Grading 

Table 

Symptoms causing no 

or minimal 

interference with 

usual social & 

functional activities 

Symptoms causing 

greater than minimal 

interference with usual 

social & functional 

activities 


inability to perform usual 


activities 


inability to perform basic 

self-care functions OR 

Medical or operative 

intervention indicated to 

prevent permanent 

impairment, persistent 

disability, or death 

SYSTEMIC 

Acute systemic 

allergic reaction 

Localized urticaria 

(wheals) with no 

medical intervention 

indicated 

Localized urticaria with 


indicated OR Mild 

angioedema with no 


indicated 

Generalized urticaria 

OR Angioedema with 


indicated OR 

Symptomatic mild 

bronchospasm 

Acute anaphylaxis OR 

Life-threatening 

bronchospasm OR 

laryngeal edema 

Chills 


or minimal 








activities 




activities 

NA 

Fatigue 

Malaise 


or minimal 








activities 




activities 

Incapacitating fatigue/ 

malaise symptoms 

causing inability to 

perform basic self-care 

functions 

Fever (nonaxillary) 37.7 – 38.6°C 38.7 – 39.3°C 39.4 – 40.5°C > 40.5°C 

Pain (indicate body 

site) 

DO NOT use for pain 

due to injection (See 

Injection Site 

Reactions: Injection 

site pain) 

See also Headache, 

Arthralgia, and 

Myalgia 

Pain causing no or 

minimal interference 

with usual social & 


Pain causing greater 

than minimal 



activities 

Pain causing inability to 

perform usual social & 


Disabling pain causing 



Hospitalization (other 

than emergency room 

visit) indicated 

Basic Self-care Functions – Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding. 

Basic Self-care Functions – Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally 

appropriate eating implement). 

Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, 

use of transportation, pursuing a hobby, etc. 

Usual Social & Functional Activities – Young Children: Activities that are age and culturally appropriate (e.g., social interactions, 

play activities, learning tasks, etc.). 

28 Dec 04/Clarification Aug 09 Page 3 of 21 Version 1.0/Clarification 1





MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Unintentional weight 

loss 

NA 

5 – 9% loss in body 

weight from baseline 

10 – 19% loss in body 

weight from baseline 

≥ 20% loss in body 

weight from baseline OR 

Aggressive intervention 

indicated [e.g., tube 

feeding or total 

parenteral nutrition 

(TPN)] 

INFECTION 

Infection (any other 

than HIV infection) 

Localized, no 

systemic antimicrobial 

treatment indicated 

AND Symptoms 

causing no or minimal 




Systemic antimicrobial 


OR Symptoms 

causing greater than 




Systemic antimicrobial 


AND Symptoms causing 



activities OR Operative 

intervention (other than 

simple incision and 

drainage) indicated 


consequences (e.g., 

septic shock) 

INJECTION SITE REACTIONS 

Injection site pain 

(pain without touching) 

Or 

Tenderness (pain 

when area is touched) 

Pain/tenderness 


limitation of use of 

limb 


limiting use of limb OR 










Pain/tenderness causing 


self-care function OR 

Hospitalization (other 

than emergency room 

visit) indicated for 

management of 

pain/tenderness 

Injection site reaction (localized) 

Adult > 15 years 

Erythema OR 

Induration 

of 5x5 cm – 9x9 cm 

(or 25 cm 2 – 81cm 2 ) 


Induration OR Edema 

> 9 cm any diameter 

(or > 81 cm 2 ) 

Ulceration OR 

Secondary infection OR 

Phlebitis OR Sterile 

abscess OR Drainage 

Necrosis (involving 

dermis and deeper 

tissue) 

Pediatric ≤ 15 

years 



present but ≤ 2.5 cm 

diameter 



> 2.5 cm diameter but 

< 50% surface area of 

the extremity segment 

(e.g., upper arm/thigh) 

Erythema OR Induration 

OR Edema involving 

≥ 50% surface area of 

the extremity segment 

(e.g., upper arm/thigh) 

OR Ulceration OR 

Secondary infection OR 

Phlebitis OR Sterile 

abscess OR Drainage 

Necrosis (involving 

dermis and deeper 

tissue) 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Pruritis associated 

with injection 

See also Skin: Pruritis 

(itching - no skin 

lesions) 

Itching localized to 

injection site AND 

Relieved 

spontaneously or with 

< 48 hours treatment 

Itching beyond the 

injection site but not 

generalized OR Itching 

localized to injection 

site requiring ≥ 48 

hours treatment 

Generalized itching 




NA 

SKIN – DERMATOLOGICAL 

Alopecia 

Thinning detectable 

by study participant 

(or by caregiver for 

young children and 

disabled adults) 

Thinning or patchy hair 

loss detectable by 

health care provider 

Complete hair loss 

NA 

Cutaneous reaction – 

rash 

Localized macular 

rash 

Diffuse macular, 

maculopapular, or 

morbilliform rash OR 

Target lesions 

Diffuse macular, 

maculopapular, or 

morbilliform rash with 

vesicles or limited 

number of bullae OR 

Superficial ulcerations 

of mucous membrane 

limited to one site 

Extensive or generalized 

bullous lesions OR 

Stevens-Johnson 

syndrome OR Ulceration 

of mucous membrane 

involving two or more 

distinct mucosal sites 

OR Toxic epidermal 

necrolysis (TEN) 

Hyperpigmentation Slight or localized Marked or generalized NA NA 

Hypopigmentation Slight or localized Marked or generalized NA NA 

Pruritis (itching – no 

skin lesions) 

(See also Injection 

Site Reactions: 

Pruritis associated 

with injection) 

Itching causing no or 




Itching causing greater 

than minimal 



activities 

Itching causing inability 

to perform usual social 

& functional activities 

NA 

CARDIOVASCULAR 

Cardiac arrhythmia 

(general) 

(By ECG or physical 

exam) 

Asymptomatic AND 

No intervention 

indicated 

Asymptomatic AND 

Non-urgent medical 

intervention indicated 

Symptomatic, non-lifethreatening 

AND Nonurgent 

medical 



arrhythmia OR Urgent 


Cardiacischemia/infarction 

NA NA Symptomatic ischemia 

(stable angina) OR 

Testing consistent with 

ischemia 

Unstable angina OR 

Acute myocardial 

infarction 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Hemorrhage 

(significant acute 

blood loss) 

NA 

Symptomatic AND No 

transfusion indicated 

Symptomatic AND 

Transfusion of ≤ 2 units 

packed RBCs (for 

children ≤ 10 cc/kg) 

indicated 


hypotension OR 

Transfusion of > 2 units 

packed RBCs (for 

children > 10 cc/kg) 

indicated 

Hypertension 


(with repeat testing 

at same visit) 

140 – 159 mmHg 

systolic 

OR 

90 – 99 mmHg 

diastolic 

160 – 179 mmHg 

systolic 

OR 

100 – 109 mmHg 

diastolic 

≥ 180 mmHg systolic 

OR 

≥ 110 mmHg diastolic 



malignant hypertension) 

OR Hospitalization 

indicated (other than 

emergency room visit) 

Correction: in Grade 2 to 160 - 179 from > 160-179 (systolic) and to ≥ 100 -109 from > 100-109 (diastolic) and 

in Grade 3 to ≥ 180 from > 180 (systolic) and to ≥ 110 from > 110 (diastolic). 


years 

(with repeat 

testing at same 

visit) 

NA 

91 st – 94 th percentile 

adjusted for age, 

height, and gender 

(systolic and/or 

diastolic) 

≥ 95 th percentile 

adjusted for age, height, 

and gender (systolic 

and/or diastolic) 



malignant hypertension) 

OR Hospitalization 



Hypotension NA Symptomatic, 

corrected with oral 

fluid replacement 

Symptomatic, IV fluids 

indicated 

Shock requiring use of 

vasopressors or 

mechanical assistance 

to maintain blood 

pressure 

Pericardial effusion 

Asymptomatic, small 

effusion requiring no 

intervention 

Asymptomatic, 

moderate or larger 

effusion requiring no 

intervention 

Effusion with non-life 

threatening physiologic 

consequences OR 

Effusion with non-urgent 




tamponade) OR Urgent 


Prolonged PR interval 


PR interval 

0.21 – 0.25 sec 

PR interval 

> 0.25 sec 

Type II 2 nd degree AV 

block OR Ventricular 

pause > 3.0 sec 

Complete AV block 


years 

1 st degree AV block 

(PR > normal for age 

and rate) 

Type I 2 nd degree AV 

block 

Type II 2 nd degree AV 

block 

Complete AV block 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Prolonged QTc 


Asymptomatic, QTc 

interval 0.45 – 0.47 

sec OR Increase 

interval < 0.03 sec 

above baseline 


interval 0.48 – 0.49 

sec OR Increase in 

interval 0.03 – 0.05 

sec above baseline 


interval ≥ 0.50 sec OR 

Increase in interval 

≥ 0.06 sec above 

baseline 


consequences, e.g. 

Torsade de pointes or 

other associated serious 

ventricular dysrhythmia 


years 


interval 0.450 – 

0.464 sec 


interval 0.465 – 

0.479 sec 


interval ≥ 0.480 sec 


consequences, e.g. 

Torsade de pointes or 

other associated serious 

ventricular dysrhythmia 

Thrombosis/embolism NA Deep vein thrombosis 

AND No intervention 

indicated (e.g., 

anticoagulation, lysis 

filter, invasive 

procedure) 

Deep vein thrombosis 

AND Intervention 

indicated (e.g., 

anticoagulation, lysis 

filter, invasive 

procedure) 

Embolic event (e.g., 

pulmonary embolism, 

life-threatening 

thrombus) 

Vasovagal episode 

(associated with a 

procedure of any kind) 

Present without loss 

of consciousness 

Present with transient 

loss of consciousness 

NA 

NA 

Ventricular 

dysfunction 

(congestive heart 

failure) 

NA 

Asymptomatic 

diagnostic finding AND 


New onset with 

symptoms OR 

Worsening symptomatic 

congestive heart failure 


congestive heart failure 

GASTROINTESTINAL 

Anorexia 

Loss of appetite 

without decreased 

oral intake 


associated with 

decreased oral intake 

without significant 

weight loss 


associated with 

significant weight loss 


consequences OR 

Aggressive intervention 

indicated [e.g., tube 

feeding or total 

parenteral nutrition 

(TPN)] 

Comment: Please note that, while the grading scale provided for Unintentional Weight Loss may be used as a guideline when 

grading anorexia, this is not a requirement and should not be used as a substitute for clinical judgment. 

Ascites Asymptomatic Symptomatic AND 

Intervention indicated 

(e.g., diuretics or 

therapeutic 

paracentesis) 

Symptomatic despite 

intervention 


consequences 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Cholecystitis NA Symptomatic AND 

Medical intervention 

indicated 

Radiologic, endoscopic, 

or operative intervention 

indicated 



sepsis or perforation) 

Constipation NA Persistent constipation 

requiring regular use 

of dietary 

modifications, 

laxatives, or enemas 

Diarrhea 

Obstipation with manual 

evacuation indicated 



obstruction) 

Adult and 

Pediatric ≥ 1 year 

Transient or 

intermittent episodes 

of unformed stools 

OR Increase of ≤ 3 

stools over baseline 

per 24-hour period 

Persistent episodes of 

unformed to watery 

stools OR Increase of 

4 – 6 stools over 

baseline per 24-hour 

period 

Bloody diarrhea OR 

Increase of ≥ 7 stools 

per 24-hour period OR 

IV fluid replacement 

indicated 



hypotensive shock) 

Pediatric < 1 year 

Liquid stools (more 

unformed than usual) 

but usual number of 

stools 

Liquid stools with 

increased number of 

stools OR Mild 

dehydration 

Liquid stools with 

moderate dehydration 

Liquid stools resulting in 

severe dehydration with 

aggressive rehydration 

indicated OR 

Hypotensive shock 

Dysphagia- 

Odynophagia 

Symptomatic but able 

to eat usual diet 


altered dietary intake 

without medical 



severely altered dietary 

intake with medical 



reduction in oral intake 

Mucositis/stomatitis 

(clinical exam) 

Indicate site (e.g., 

larynx, oral) 

See Genitourinary for 

Vulvovaginitis 

Erythema of the 

mucosa 

Patchy 

pseudomembranes or 

ulcerations 

Confluent 

pseudomembranes or 

ulcerations OR Mucosal 

bleeding with minor 

trauma 

Tissue necrosis OR 

Diffuse spontaneous 

mucosal bleeding OR 



aspiration, choking) 

See also Dysphagia- 

Odynophagia and 

Proctitis 

Nausea 

Transient (< 24 hours) 

or intermittent nausea 

with no or minimal 

interference with oral 

intake 

Persistent nausea 

resulting in decreased 

oral intake for 24 – 48 

hours 

Persistent nausea 

resulting in minimal oral 

intake for > 48 hours 

OR Aggressive 

rehydration indicated 

(e.g., IV fluids) 
















MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Pancreatitis NA Symptomatic AND 

Hospitalization not 



Symptomatic AND 

Hospitalization indicated 

(other than emergency 

room visit) 



circulatory failure, 

hemorrhage, sepsis) 

Proctitis (functionalsymptomatic) 

Also see 

Mucositis/stomatitis 

for clinical exam 

Rectal discomfort 

AND No intervention 

indicated 





activities OR Medical 





activities OR Operative 




perforation) 

Vomiting 

Transient or 

intermittent vomiting 


interference with oral 

intake 

Frequent episodes of 

vomiting with no or 

mild dehydration 

Persistent vomiting 

resulting in orthostatic 

hypotension OR 

Aggressive rehydration 

indicated (e.g., IV fluids) 




NEUROLOGIC 

Alteration in 

personality-behavior 

or in mood (e.g., 

agitation, anxiety, 

depression, mania, 

psychosis) 

Alteration causing no 

or minimal 




Alteration causing 




activities 

Alteration causing 



activities 

Behavior potentially 

harmful to self or others 

(e.g., suicidal and 

homicidal ideation or 

attempt, acute 

psychosis) OR Causing 


self-care functions 

Altered Mental Status 

For Dementia, see 

Cognitive and 

behavioral/attentional 

disturbance (including 

dementia and 

attention deficit 

disorder) 

Changes causing no 

or minimal 




Mild lethargy or 

somnolence causing 




activities 

Confusion, memory 

impairment, lethargy, or 

somnolence causing 



activities 

Delirium OR 

obtundation, OR coma 

Ataxia 

Asymptomatic ataxia 

detectable on exam 

OR Minimal ataxia 





Symptomatic ataxia 





Symptomatic ataxia 




Disabling ataxia causing 















MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Cognitive and 

behavioral/attentional 

disturbance (including 

dementia and 

attention deficit 

disorder) 

Disability causing no 

or minimal 




OR Specialized 

resources not 

indicated 

Disability causing 




activities OR 

Specialized resources 

on part-time basis 

indicated 




activities OR 

Specialized resources 

on a full-time basis 

indicated 




Institutionalization 

indicated 

CNS ischemia 

(acute) 

NA NA Transient ischemic 

attack 

Cerebral vascular 

accident (CVA, stroke) 

with neurological deficit 

Developmental delay 

– Pediatric ≤ 16 

years 

Mild developmental 

delay, either motor or 

cognitive, as 

determined by 

comparison with a 

developmental 

screening tool 

appropriate for the 

setting 

Moderate 

developmental delay, 

either motor or 

cognitive, as 

determined by 


developmental 



setting 

Severe developmental 

delay, either motor or 

cognitive, as determined 

by comparison with a 

developmental 



setting 

Developmental 

regression, either motor 

or cognitive, as 

determined by 


developmental 



setting 

Headache 


or minimal 








activities 




activities 




Hospitalization indicated 

(other than emergency 

room visit) OR 

Headache with 

significant impairment of 

alertness or other 

neurologic function 

Insomnia NA Difficulty sleeping 





Difficulty sleeping 




Disabling insomnia 



functions 

Neuromuscular 

weakness 

(including myopathy & 

neuropathy) 

Asymptomatic with 

decreased strength 

on exam OR Minimal 

muscle weakness 





Muscle weakness 





Muscle weakness 




Disabling muscle 

weakness causing 



Respiratory muscle 

weakness impairing 

ventilation 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Neurosensory 

alteration (including 

paresthesia and 

painful neuropathy) 

Asymptomatic with 

sensory alteration on 

exam or minimal 

paresthesia causing 

no or minimal 




Sensory alteration or 





activities 

Sensory alteration or 




activities 

Disabling sensory 

alteration or paresthesia 



functions 

Seizure: (new onset) 

– Adult ≥ 18 years 

See also Seizure: 

(known pre-existing 

seizure disorder) 

NA 1 seizure 2 – 4 seizures Seizures of any kind 

which are prolonged, 

repetitive (e.g., status 

epilepticus), or difficult 

to control (e.g., 

refractory epilepsy) 

Seizure: (known preexisting 

seizure 

disorder) 

– Adult ≥ 18 years 

For worsening of 

existing epilepsy the 

grades should be 

based on an increase 

from previous level of 

control to any of these 

levels. 

NA 

Increased frequency of 

pre-existing seizures 

(non-repetitive) without 

change in seizure 

character OR 

Infrequent breakthrough 

seizures while 

on stable medication 

in a previously 

controlled seizure 

disorder 

Change in seizure 

character from baseline 

either in duration or 

quality (e.g., severity or 

focality) 

Seizures of any kind 

which are prolonged, 

repetitive (e.g., status 

epilepticus), or difficult 

to control (e.g., 

refractory epilepsy) 

Seizure 

– Pediatric < 18 

years 

Seizure, generalized 

onset with or without 

secondary 

generalization, lasting 

< 5 minutes with < 24 

hours post ictal state 



secondary 


5 – 20 minutes with 

< 24 hours post ictal 

state 



secondary 


> 20 minutes 



secondary 

generalization, requiring 

intubation and sedation 

Syncope (not 

associated with a 

procedure) 

NA Present NA NA 

Vertigo 

Vertigo causing no or 




Vertigo causing 




activities 

Vertigo causing inability 

to perform usual social 

& functional activities 

Disabling vertigo 



functions 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


RESPIRATORY 

Bronchospasm (acute) 

FEV1 or peak flow 

reduced to 

70 – 80% 


50 – 69% 


25 – 49% 

Cyanosis OR FEV1 or 

peak flow < 25% OR 

Intubation 

Dyspnea or respiratory distress 

Adult ≥ 14 years 

Dyspnea on exertion 





Dyspnea on exertion 





Dyspnea at rest causing 



activities 

Respiratory failure with 

ventilatory support 

indicated 

Pediatric < 14 

years 

Wheezing OR 

minimal increase in 

respiratory rate for 

age 

Nasal flaring OR 

Intercostal retractions 

OR Pulse oximetry 90 

– 95% 

Dyspnea at rest causing 



activities OR Pulse 

oximetry < 90% 

Respiratory failure with 

ventilatory support 

indicated 

MUSCULOSKELETAL 

Arthralgia 

See also Arthritis 

Joint pain causing no 

or minimal 




Joint pain causing 




activities 

Joint pain causing 



activities 

Disabling joint pain 



functions 

Arthritis 

See also Arthralgia 

Stiffness or joint 

swelling causing no or 





swelling causing 




activities 


swelling causing 



activities 

Disabling joint stiffness 

or swelling causing 



Bone Mineral Loss 


BMD t-score 

-2.5 to -1.0 

BMD t-score < -2.5 

Pathological fracture 

(including loss of 

vertebral height) 

Pathologic fracture 

causing life-threatening 

consequences 

Pediatric < 21 

years 

BMD z-score 

-2.5 to -1.0 

BMD z-score < -2.5 

Pathological fracture 

(including loss of 

vertebral height) 

Pathologic fracture 

causing life-threatening 

consequences 

Myalgia 

(non-injection site) 

Muscle pain causing 

no or minimal 








activities 




activities 

Disabling muscle pain 



functions 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Osteonecrosis NA Asymptomatic with 

radiographic findings 

AND No operative 


GENITOURINARY 

Symptomatic bone pain 

with radiographic 

findings OR Operative 


Disabling bone pain with 

radiographic findings 



functions 

Cervicitis 

(symptoms) 

(For use in studies 

evaluating topical 

study agents) 

For other cervicitis see 

Infection: Infection 

(any other than HIV 

infection) 


or minimal 








activities 




activities 




Cervicitis 


(For use in studies 


study agents) 

For other cervicitis see 



infection) 

Minimal cervical 

abnormalities on 

examination 

(erythema, 

mucopurulent 

discharge, or friability) 

OR Epithelial 

disruption 

< 25% of total surface 

Moderate cervical 


examination 

(erythema, 

mucopurulent 


OR Epithelial 

disruption of 25 – 49% 

total surface 

Severe cervical 


examination (erythema, 

mucopurulent 


OR Epithelial disruption 

50 – 75% total surface 

Epithelial disruption 

> 75% total surface 

Inter-menstrual 

bleeding (IMB) 

Spotting observed by 

participant OR 

Minimal blood 

observed during 

clinical or colposcopic 

examination 

Inter-menstrual 

bleeding not greater in 

duration or amount 

than usual menstrual 

cycle 

Inter-menstrual bleeding 

greater in duration or 

amount than usual 

menstrual cycle 

Hemorrhage with lifethreatening 

hypotension 

OR Operative 


Urinary tract 

obstruction (e.g., 

stone) 

NA 

Signs or symptoms of 

urinary tract 

obstruction without 

hydronephrosis or 

renal dysfunction 

Signs or symptoms of 

urinary tract obstruction 

with hydronephrosis or 

renal dysfunction 

Obstruction causing lifethreatening 

consequences 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 



(symptoms) 

(Use in studies 


study agents) 


or minimal 








activities 




activities 




For other 

vulvovaginitis see 



infection) 



(Use in studies 


study agents) 

Minimal vaginal 


examination OR 


< 25% of total surface 

Moderate vaginal 



Epithelial disruption of 

25 - 49% total surface 

Severe vaginal 




50 - 75% total surface 

Vaginal perforation OR 


> 75% total surface 

For other 

vulvovaginitis see 



infection) 

OCULAR/VISUAL 

Uveitis 

Asymptomatic but 

detectable on exam 

Symptomatic anterior 

uveitis OR Medical 


Posterior or pan-uveitis 

OR Operative 


Disabling visual loss in 

affected eye(s) 

Visual changes (from 

baseline) 

Visual changes 





Visual changes 





Visual changes causing 



activities 

Disabling visual loss in 

affected eye(s) 

ENDOCRINE/METABOLIC 

Abnormal fat 

accumulation 

(e.g., back of neck, 

breasts, abdomen) 

Detectable by study 

participant (or by 

caregiver for young 

children and disabled 

adults) 

Detectable on physical 

exam by health care 

provider 

Disfiguring OR Obvious 

changes on casual 

visual inspection 

NA 

Diabetes mellitus NA New onset without 

need to initiate 

medication OR 

Modification of current 

medications to regain 

glucose control 

New onset with initiation 

of medication indicated 

OR Diabetes 

uncontrolled despite 

treatment modification 



ketoacidosis, 

hyperosmolar nonketotic 

coma) 













MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Gynecomastia 


participant or 

caregiver (for young 


adults) 



provider 


on casual visual 

inspection 

NA 

Hyperthyroidism Asymptomatic Symptomatic causing 




activities OR Thyroid 

suppression therapy 

indicated 

Hypothyroidism Asymptomatic Symptomatic causing 




activities OR Thyroid 

replacement therapy 

indicated 




activities OR 

Uncontrolled despite 





activities OR 

Uncontrolled despite 




thyroid storm) 



myxedema coma) 

Lipoatrophy 

(e.g., fat loss from the 

face, extremities, 

buttocks) 


participant (or by 

caregiver for young 


adults) 



provider 


on casual visual 

inspection 

NA 












LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


HEMATOLOGY 

Standard International Units are listed in italics 

Absolute CD4+ count 

– Adult and Pediatric 

> 13 years 

(HIV NEGATIVE ONLY) 

Absolute lymphocyte 

count 

– Adult and Pediatric 

> 13 years 

(HIV NEGATIVE ONLY) 

300 – 400/mm 3 

300 – 400/µL 

600 – 650/mm 3 

0.600 x 10 9 – 

0.650 x 10 9 /L 

200 – 299/mm 3 

200 – 299/µL 

500 – 599/mm 3 

0.500 x 10 9 – 

0.599 x 10 9 /L 

100 – 199/mm 3 

100 – 199/µL 

350 – 499/mm 3 

0.350 x 10 9 – 

0.499 x 10 9 /L 

< 100/mm 3 

< 100/µL 

< 350/mm 3 

< 0.350 x 10 9 /L 

Comment: Values in children ≤ 13 years are not given for the two parameters above because the absolute counts are variable. 

Absolute neutrophil count (ANC) 

Adult and Pediatric, 

> 7 days 

1,000 – 1,300/mm 3 

1.000 x 10 9 – 

1.300 x 10 9 /L 

Infant ∗† , 2 – ≤ 7 days 1,250 – 1,500/mm 3 

1.250 x 10 9 – 

1.500 x 10 9 /L 

Infant ∗† , ≤1 day 4,000 – 5,000/mm 3 

4.000 x 10 9 – 

5.000 x 10 9 /L 

750 – 999/mm 3 

0.750 x 10 9 – 

0.999 x 10 9 /L 

1,000 – 1,249/mm 3 

1.000 x 10 9 – 

1.249 x 10 9 /L 

3,000 – 3,999/mm 3 

3.000 x 10 9 – 

3.999 x10 9 /L 

Comment: Parameter changed from “Infant, < 1 day” to “Infant, ≤1 day” 

Fibrinogen, decreased 

100 – 200 mg/dL 

1.00 – 2.00 g/L 

OR 

0.75 – 0.99 x LLN 

75 – 99 mg/dL 

0.75 – 0.99 g/L 

OR 

0.50 – 0.74 x LLN 

500 – 749/mm 3 

0.500 x 10 9 – 

0.749 x 10 9 /L 

750 – 999/mm 3 

0.750 x 10 9 – 

0.999 x 10 9 /L 

1,500 – 2,999/mm 3 

1.500 x 10 9 – 

2.999 x 10 9 /L 

50 – 74 mg/dL 

0.50 – 0.74 g/L 

OR 

0.25 – 0.49 x LLN 

< 500/mm 3 

< 0.500 x 10 9 /L 

< 750/mm 3 

< 0.750 x 10 9 /L 

< 1,500/mm 3 

< 1.500 x 10 9 /L 

< 50 mg/dL 

< 0.50 g/L 

OR 

< 0.25 x LLN 

OR 

Associated with gross 

bleeding 

∗ 

Values are for term infants. Preterm infants should be assessed using local normal ranges. 

† 

Use age and sex appropriate values (e.g., bilirubin). 

28 Dec-04/Clarification Aug 09 Page 16 of 21 Version 1.0/Clarification 1




LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Hemoglobin (Hgb) 

Comment: The Hgb values in mmol/L have changed because the conversion factor used to convert g/dL to mmol/L has been 

changed from 0.155 to 0.6206 (the most commonly used conversion factor). For grading Hgb results obtained by an analytic 

method with a conversion factor other than 0.6206, the result must be converted to g/dL using the appropriate conversion factor 

for that lab. 

8.5 – 10.0 g/dL 7.5 – 8.4 g/dL 

6.50 – 7.4 g/dL < 6.5 g/dL 

5.24 – 6.23 mmol/L 4.62–5.23 mmol/L 4.03–4.61 mmol/L < 4.03 mmol/L 

Adult and Pediatric 

≥ 57 days 

(HIV POSITIVE ONLY) 


≥ 57 days 

(HIV NEGATIVE 

ONLY) 

10.0 – 10.9 g/dL 

6.18 – 6.79 mmol/L 

OR 

Any decrease 

2.5 – 3.4 g/dL 

1.58 – 2.13 mmol/L 

Comment: The decrease is a decrease from baseline 

Infant ∗† , 36 – 56 days 

(HIV POSITIVE OR 

NEGATIVE) 

Infant ∗† , 22 – 35 days 


NEGATIVE) 

Infant ∗† , ≤ 21 days 


NEGATIVE) 

8.5 – 9.4 g/dL 

5.24 – 5.86 mmol/L 

9.5 – 10.5 g/dL 

5.87 - 6.54 mmol/L 

12.0 – 13.0 g/dL 

7.42 – 8.09 mmol/L 

9.0 – 9.9 g/dL 

5.55 - 6.17 mmol/L 

OR 

Any decrease 

3.5 – 4.4 g/dL 

2.14 – 2.78 mmol/L 

7.0 – 8.4 g/dL 

4.31 – 5.23 mmol/L 

8.0 – 9.4 g/dL 

4.93 – 5.86 mmol/L 

10.0 – 11.9 g/dL 

6.18 – 7.41 mmol/L 

Correction: Parameter changed from “Infant < 21 days” to “Infant ≤ 21 days” 

International Normalized 

Ratio of prothrombin time 

(INR) 

7.0 – 8.9 g/dL 

4.34 - 5.54 mmol/L 

OR 

Any decrease 

≥ 4.5 g/dL 

> 2.79 mmol/L 

6.0 – 6.9 g/dL 

3.72 – 4.30 mmol/L 

7.0 – 7.9 g/dL 

4.34 – 4.92 mmol/L 

9.0 – 9.9 g/dL 

5.59- 6.17 mmol/L 

< 7.0 g/dL 

< 4.34 mmol/L 

< 6.00 g/dL 

< 3.72 mmol/L 

< 7.00 g/dL 

< 4.34 mmol/L 

< 9.0 g/dL 

< 5.59 mmol/L 

1.1 – 1.5 x ULN 1.6 – 2.0 x ULN 2.1 – 3.0 x ULN > 3.0 x ULN 

Methemoglobin 5.0 – 10.0% 10.1 – 15.0% 15.1 – 20.0% > 20.0% 

Prothrombin Time (PT) 1.1 – 1.25 x ULN 1.26 – 1.50 x ULN 1.51 – 3.00 x ULN > 3.00 x ULN 

Partial Thromboplastin 

Time (PTT) 

Platelets, decreased 100,000 – 

124,999/mm 3 

100.000 x 10 9 – 

124.999 x 10 9 /L 

WBC, decreased 2,000 – 2,500/mm 3 


2.000 x 10 9 – 

2.500 x 10 9 /L 

50,000 – 

99,999/mm 3 

50.000 x 10 9 – 

99.999 x 10 9 /L 

1,500 – 1,999/mm 3 

1.500 x 10 9 – 

1.999 x 10 9 /L 

25,000 – 

49,999/mm 3 

25.000 x 10 9 – 

49.999 x 10 9 /L 

1,000 – 1,499/mm 3 

1.000 x 10 9 – 

1.499 x 10 9 /L 

< 25,000/mm 3 

< 25.000 x 10 9 /L 

< 1,000/mm 3 

< 1.000 x 10 9 /L 

∗ 


† 






LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


CHEMISTRIES 


Acidosis NA pH < normal, but ≥ 7.3 pH < 7.3 without lifethreatening 

consequences 

Albumin, serum, low 

3.0 g/dL – < LLN 

30 g/L – < LLN 

2.0 – 2.9 g/dL 

20 – 29 g/L 

< 2.0 g/dL 

< 20 g/L 

pH < 7.3 with lifethreatening 

consequences 

Alkaline Phosphatase 1.25 – 2.5 x ULN † 2.6 – 5.0 x ULN † 5.1 – 10.0 x ULN † > 10.0 x ULN † 

Alkalosis NA pH > normal, but ≤ 7.5 pH > 7.5 without lifethreatening 

consequences 

NA 

pH > 7.5 with lifethreatening 

consequences 

ALT (SGPT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 

AST (SGOT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 

Bicarbonate, serum, low 

16.0 mEq/L – < LLN 

16.0 mmol/L – < LLN 

11.0 – 15.9 mEq/L 

11.0 – 15.9 mmol/L 

8.0 – 10.9 mEq/L 

8.0 – 10.9 mmol/L 

< 8.0 mEq/L 

< 8.0 mmol/L 

Comment: Some laboratories will report this value as Bicarbonate (HCO 3 ) and others as Total Carbon Dioxide (CO 2 ). These 

are the same tests; values should be graded according to the ranges for Bicarbonate as listed above. 

Bilirubin (Total) 

Adult and Pediatric > 

14 days 


(non-hemolytic) 


(hemolytic) 

Calcium, serum, high 


≥ 7 days 

Infant ∗† , < 7 days 

Calcium, serum, low 


≥ 7 days 

Infant ∗† , < 7 days 


NA 

20.0 – 25.0 mg/dL 

342 – 428 µmol/L 

25.1 – 30.0 mg/dL 

429 – 513 µmol/L 

NA NA 20.0 – 25.0 mg/dL 

342 – 428 µmol/L 

10.6 – 11.5 mg/dL 

2.65 – 2.88 mmol/L 

11.5 – 12.4 mg/dL 

2.88 – 3.10 mmol/L 

7.8 – 8.4 mg/dL 

1.95 – 2.10 mmol/L 

6.5 – 7.5 mg/dL 

1.63 – 1.88 mmol/L 

11.6 – 12.5 mg/dL 

2.89 – 3.13 mmol/L 

12.5 – 12.9 mg/dL 

3.11 – 3.23 mmol/L 

7.0 – 7.7 mg/dL 

1.75 – 1.94 mmol/L 

6.0 – 6.4 mg/dL 

1.50 – 1.62 mmol/L 

Comment: Do not adjust Calcium, serum, low or Calcium, serum, high for albumin 

12.6 – 13.5 mg/dL 

3.14 – 3.38 mmol/L 

13.0 – 13.5 mg/dL 

3.245 – 3.38 mmol/L 

6.1 – 6.9 mg/dL 

1.53 – 1.74 mmol/L 

5.50 – 5.90 mg/dL 

1.38 – 1.51 mmol/L 

> 30.0 mg/dL 

> 513.0 µmol/L 

> 25.0 mg/dL 

> 428 µmol/L 

> 13.5 mg/dL 

> 3.38 mmol/L 

> 13.5 mg/dL 

> 3.38 mmol/L 

< 6.1 mg/dL 

< 1.53 mmol/L 

< 5.50 mg/dL 

< 1.38 mmol/L 

∗ 


† 






LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Cardiac troponin I (cTnI) NA NA NA Levels consistent with 

myocardial infarction 

or unstable angina as 

defined by the 

manufacturer 

Cardiac troponin T (cTnT) NA NA NA ≥ 0.20 ng/mL 

OR 

Levels consistent with 

myocardial infarction 

or unstable angina as 

defined by the 

manufacturer 

Cholesterol (fasting) 


Pediatric < 18 years 

200 – 239 mg/dL 

5.18 – 6.19 mmol/L 

170 – 199 mg/dL 

4.40 – 5.15 mmol/L 

240 – 300 mg/dL 

6.20 – 7.77 mmol/L 

200 – 300 mg/dL 

5.16 – 7.77 mmol/L 

> 300 mg/dL 

> 7.77 mmol/L 

> 300 mg/dL 

> 7.77 mmol/L 

Creatine Kinase 3.0 – 5.9 x ULN † 6.0 – 9.9 x ULN † 10.0 – 19.9 x ULN † ≥ 20.0 x ULN † 

Creatinine 1.1 – 1.3 x ULN † 1.4 – 1.8 x ULN † 1.9 – 3.4 x ULN † ≥ 3.5 x ULN † 

NA 

NA 

LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Glucose, serum, high 

Nonfasting 

116 – 160 mg/dL 

6.44 – 8.88 mmol/L 

161 – 250 mg/dL 

8.89 – 13.88 mmol/L 

251 – 500 mg/dL 

13.89 – 27.75 mmol/L 

> 500 mg/dL 

> 27.75 mmol/L 

Fasting 

110 – 125 mg/dL 

6.11 – 6.94 mmol/L 

126 – 250 mg/dL 

6.95 – 13.88 mmol/L 

251 – 500 mg/dL 

13.89 – 27.75 mmol/L 

> 500 mg/dL 

> 27.75 mmol/L 

Glucose, serum, low 


≥ 1 month 

55 – 64 mg/dL 

3.05 – 3.55 mmol/L 

40 – 54 mg/dL 

2.22 – 3.06 mmol/L 

30 – 39 mg/dL 

1.67 – 2.23 mmol/L 

< 30 mg/dL 

< 1.67 mmol/L 

Infant ∗† , < 1 month 

50 – 54 mg/dL 

2.78 – 3.00 mmol/L 

40 – 49 mg/dL 

2.22 – 2.77 mmol/L 

30 – 39 mg/dL 

1.67 – 2.21 mmol/L 

< 30 mg/dL 

< 1.67 mmol/L 

Lactate 

ULN - < 2.0 x ULN 

without acidosis 

≥ 2.0 x ULN without 

acidosis 

Increased lactate with 

pH < 7.3 without lifethreatening 

consequences 

Increased lactate with 

pH < 7.3 with lifethreatening 

consequences 

∗ 


† 






Comment: Added ULN to Grade 1 parameter 

LDL cholesterol (fasting) 


Pediatric > 2 - < 18 

years 

130 – 159 mg/dL 

3.37 – 4.12 mmol/L 

110 – 129 mg/dL 

2.85 – 3.34 mmol/L 

160 – 190 mg/dL 

4.13 – 4.90 mmol/L 

130 – 189 mg/dL 

3.35 – 4.90 mmol/L 

≥ 190 mg/dL 

≥ 4.91 mmol/L 

≥ 190 mg/dL 

≥ 4.91 mmol/L 

Lipase 1.1 – 1.5 x ULN 1.6 – 3.0 x ULN 3.1 – 5.0 x ULN > 5.0 x ULN 

Magnesium, serum, low 

1.2 – 1.4 mEq/L 

0.60 – 0.70 mmol/L 

0.9 – 1.1 mEq/L 

0.45 – 0.59 mmol/L 

0.6 – 0.8 mEq/L 

0.30 – 0.44 mmol/L 

NA 

NA 

< 0.60 mEq/L 

< 0.30 mmol/L 

Pancreatic amylase 1.1 – 1.5 x ULN 1.6 – 2.0 x ULN 2.1 – 5.0 x ULN > 5.0 x ULN 

Phosphate, serum, low 


> 14 years 

Pediatric 1 year – 14 

years 

Pediatric < 1 year 

Potassium, serum, high 

Potassium, serum, low 

Sodium, serum, high 

Sodium, serum, low 

2.5 mg/dL – < LLN 

0.81 mmol/L – < LLN 

3.0 – 3.5 mg/dL 

0.97 – 1.13 mmol/L 

3.5 – 4.5 mg/dL 

1.13 – 1.45 mmol/L 

5.6 – 6.0 mEq/L 

5.6 – 6.0 mmol/L 

3.0 – 3.4 mEq/L 

3.0 – 3.4 mmol/L 

146 – 150 mEq/L 

146 – 150 mmol/L 

130 – 135 mEq/L 

130 – 135 mmol/L 

2.0 – 2.4 mg/dL 

0.65 – 0.80 mmol/L 

2.5 – 2.9 mg/dL 

0.81 – 0.96 mmol/L 

2.5 – 3.4 mg/dL 

0.81 – 1.12 mmol/L 

6.1 – 6.5 mEq/L 

6.1 – 6.5 mmol/L 

2.5 – 2.9 mEq/L 

2.5 – 2.9 mmol/L 

151 – 154 mEq/L 

151 – 154 mmol/L 

125 – 129 mEq/L 

125 – 129 mmol/L 

Triglycerides (fasting) NA 500 – 750 mg/dL 

5.65 – 8.48 mmol/L 

1.0 – 1.9 mg/dL 

0.32 – 0.64 mmol/L 

1.5 – 2.4 mg/dL 

0.48 – 0.80 mmol/L 

1.5 – 2.4 mg/dL 

0.48 – 0.80 mmol/L 

6.6 – 7.0 mEq/L 

6.6 – 7.0 mmol/L 

2.0 – 2.4 mEq/L 

2.0 – 2.4 mmol/L 

155 – 159 mEq/L 

155 – 159 mmol/L 

121 – 124 mEq/L 

121 – 124 mmol/L 

751 – 1,200 mg/dL 

8.49 – 13.56 mmol/L 

< 1.00 mg/dL 

< 0.32 mmol/L 

< 1.50 mg/dL 

< 0.48 mmol/L 

< 1.50 mg/dL 

< 0.48 mmol/L 

> 7.0 mEq/L 

> 7.0 mmol/L 

< 2.0 mEq/L 

< 2.0 mmol/L 

≥ 160 mEq/L 

≥ 160 mmol/L 

≤ 120 mEq/L 

≤ 120 mmol/L 

> 1,200 mg/dL 

> 13.56 mmol/L 

∗ 


† 






LABORATORY 


MILD 

GRADE 2 

MODERATE 

GRADE 3 

SEVERE 

GRADE 4 

POTENTIALLY 


Uric acid 

7.5 – 10.0 mg/dL 

0.45 – 0.59 mmol/L 

10.1 – 12.0 mg/dL 

0.60 – 0.71 mmol/L 

12.1 – 15.0 mg/dL 

0.72 – 0.89 mmol/L 

> 15.0 mg/dL 

> 0.89 mmol/L 

URINALYSIS 


Hematuria (microscopic) 6 – 10 RBC/HPF > 10 RBC/HPF Gross, with or without 

clots OR with RBC 

casts 

Transfusion indicated 

Proteinuria, random 

collection 

1 + 2 – 3 + 4 + NA 

Proteinuria, 24 hour collection 


≥ 10 years 

200 – 999 mg/24 h 

0.200 – 0.999 g/d 

1,000 – 1,999 mg/24 h 

1.000 – 1.999 g/d 

2,000 – 3,500 mg/24 h 

2.000 – 3.500 g/d 

> 3,500 mg/24 h 

> 3.500 g/d 

Pediatric > 3 mo - 

< 10 years 

201 – 499 mg/m 2 /24 h 

0.201 – 0.499 g/d 

500 – 799 mg/m 2 /24 h 

0.500 – 0.799 g/d 

800 – 1,000 

mg/m 2 /24 h 

0.800 – 1.000 g/d 

> 1,000 mg/ m 2 /24 h 

> 1.000 g/d 

∗ 


†

DAIDS Table for Grading the Severity of Adult and Pediatric Adverse ...

Create successful ePaper yourself

Delete template?

Save as template?